Inflammatory biomarkers and risk of cancer in 84,000 individuals from the general population

International Journal of Cancer

Volumn 139, Issue 7, 2016, Pages 1493-1500

  Allin, Kristine H ^a,b   Bojesen, Stig E ^a,c   Nordestgaard, Børge G ^a,c  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Capital Region   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

C reactive protein; colorectal cancer; fibrinogen; inflammation; lung cancer; whole blood leukocyte count

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; FIBRINOGEN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; INFLAMMATION; LEUKOCYTE COUNT; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DETERMINATION; PROTEIN FUNCTION; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM;

EID: 84978304046     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30194     Document Type: Article

References (35)

1. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357:539–45.
2. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860–7.
3. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140:883–99.
4. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature 2008; 454:436–44.
5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57–70.
6. Colotta F, Allavena P, Sica A, et al. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009; 30:1073–81.
7. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646–74.
8. Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 2009; 27:2217–24.
9. Chaturvedi AK, Caporaso NE, Katki HA, et al. C-reactive protein and risk of lung cancer. J Clin Oncol 2010; 28:2719–26.
10. Il'yasova D, Colbert LH, Harris TB, et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 2005; 14:2413–8.
11. Siemes C, Visser LE, Coebergh JW, et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol 2006; 24:5216–22.
12. Touvier M, Fezeu L, Ahluwalia N, et al. Association between prediagnostic biomarkers of inflammation and endothelial function and cancer risk: a nested case-control study. Am J Epidemiol 2013; 177:3–13.
13. Trichopoulos D, Psaltopoulou T, Orfanos P, et al. Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev 2006; 15:381–4.
14. Zhou B, Liu J, Wang ZM, et al. C-reactive protein, interleukin 6 and lung cancer risk: a meta-analysis. PLoS One 2012; 7:e43075.
15. Chan DS, Bandera EV, Greenwood DC, et al. Circulating C-reactive protein and breast cancer risk-systematic literature review and meta-analysis of prospective cohort studies. Cancer Epidemiol Biomarkers Prev 2015; 24:1439–49.
16. Zhou B, Shu B, Yang J, et al. C-reactive protein, interleukin-6 and the risk of colorectal cancer: a meta-analysis. Cancer Causes Control 2014; 25:1397–405.
17. Prizment AE, Anderson KE, Visvanathan K, et al. Association of inflammatory markers with colorectal cancer incidence in the atherosclerosis risk in communities study. Cancer Epidemiol Biomarkers Prev 2011; 20:297–307.
18. dos Santos Silva I, De Stavola BL, Pizzi C, et al. Circulating levels of coagulation and inflammation markers and cancer risks: individual participant analysis of data from three long-term cohorts. Int J Epidemiol 2010; 39:699–709.
19. Margolis KL, Rodabough RJ, Thomson CA, et al. Prospective study of leukocyte count as a predictor of incident breast, colorectal, endometrial, and lung cancer and mortality in postmenopausal women. Arch Intern Med 2007; 167:1837–44.
20. Toriola AT, Laukkanen JA, Kurl S, et al. Prediagnostic circulating markers of inflammation and risk of prostate cancer. Int J Cancer 2013; 133:2961–7.
21. van Hemelrijck M, Holmberg L, Garmo H, et al. Association between levels of C-reactive protein and leukocytes and cancer: three repeated measurements in the Swedish AMORIS study. Cancer Epidemiol Biomarkers Prev 2011; 20:428–37.
22. Rode L, Nordestgaard BG, Bojesen SE. Peripheral blood leukocyte telomere length and mortality among 64,637 individuals from the general population. J Natl Cancer Inst 2015; 107:djv074.
23. Christensen S, Johansen MB, Christiansen CF, et al. Comparison of Charlson comorbidity index with SAPS and APACHE scores for prediction of mortality following intensive care. Clin Epidemiol 2011; 3:203–11.
24. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43:1130–9.
25. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373–83.
26. Quan H, Li B, Couris CM, et al. Updating and validating the charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 2011; 173:676–82.
27. Storm HH. Completeness of cancer registration in Denmark 1943-1966 and efficacy of record linkage procedures. Int J Epidemiol 1988; 17:44–9.
28. Storm HH. The Danish Cancer Registry, a self-reporting national cancer registration system with elements of active data collection. IARC Sci Publ 1991;95:220–36.
29. Storm HH, Michelsen EV, Clemmensen IH, et al. The Danish Cancer Registry–history, content, quality and use. Dan Med Bull 1997; 44:535–9.
30. Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk. J Am Stat Assoc 1999; 94:496–509.
31. National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365:395–409.
32. Farquhar C, Marjoribanks J, Lethaby A, et al. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2009; CD004143.
33. Cole SW. Chronic inflammation and breast cancer recurrence. J Clin Oncol 2009; 27:3418–9.
34. De Marzo AM, Platz EA, Sutcliffe S, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7:256–69.
35. Clarke R, Shipley M, Lewington S, et al. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol 1999; 150:341–53.